Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study (Q37989260)
Jump to navigation
Jump to search
scientific article published on 28 February 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study |
scientific article published on 28 February 2012 |
Statements
1 reference
Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study (English)
1 reference
Emmanuelle Charafe-Jauffret
0 references
Thomas Bachelot
1 reference
Jean-Yves Pierga
1 reference
Thierry Petit
1 reference
Thierry Delozier
1 reference
Jean-Marc Ferrero
1 reference
Mario Campone
1 reference
Florence Lerebours
1 reference
Henri Roché
1 reference
Maria Pavlyuk
1 reference
Sandrine Kraemer
1 reference
28 February 2012
1 reference
1 reference
Identifiers
1 reference